Differential Inhibition by Aspirin of Vascular and Platelet Prostaglandin Synthesis in Atherosclerotic Patients

New England Journal of Medicine

Volumn 308, Issue 14, 1983, Pages 800-805

  Weksler, Babette B ^a   Pett, Stuart B ^a   Alonso, Daniel ^a   Richter, Richard C ^a   Stelzer, Paul ^a   Subramanian, Valavanur ^a   Tack Goldman, Karen ^a   Gay, William A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 9ALPHA,11ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; PROSTAGLANDIN; THROMBOXANE A2;

AORTA; ATHEROSCLEROSIS; BLOOD AND HEMOPOIETIC SYSTEM; BLOOD VESSEL WALL; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; GREAT BLOOD VESSEL; HEART; HUMAN; PERIPHERAL VASCULAR SYSTEM; THROMBOCYTE AGGREGATION;

EID: 0020537396     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198304073081402     Document Type: Article

References (27)

1. Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature (New Biol). 1971; 231: 235–7.
2. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA. 1975; 72: 3073–6.
3. Burch JW, Baenziger NL, Stanford N, Majerus PW. Sensitivity of fatty acid cyclooxygenase from human aorta to acetylation by aspirin. Proc Natl Acad Sci USA. 1978; 75: 5181–4.
4. Pareti FI, D'Angelo A, Mannucci PM, Smith JB. Platelets and the vessel wall: how much aspirin? Lancet. 1980; 1: 371–2.
5. Preston FE, Whipps S, Jackson CA, French AJ, Wyld PJ, Stoddard CJ. Inhibition of prostacyclin and platelet THROMBOXANE A2 after low-dose aspirin. N Engl J Med. 1981; 304: 76–9.
6. Hanley SP, Bevan J, Cockbill SR, Heptinstall S. Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. Lancet. 1981; 1: 969–71.
7. Masotti G, Galanti G, Poggesi L, Abbate R, Neri Sernen GG. Differential inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet. 1979; 2: 1213–6.
8. Jaffe EA, Weksler BB. Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. J Clin Invest. 1979; 63: 532–5.
9. Kelton JG, Hirsh J, Carter CJ, Buchanan MR. Thrombogenic effect of highdose aspirin in rabbits: relationship to inhibition of vessel wall synthesis of prostaglandin I2-like activity. J Clin Invest. 1978; 62: 892–5.
10. Wu KK, Chen Y-C, Fordham E, Ts'ao C-H. Rayudu G, Matayoshi D. Differential effects of two doses of aspirin on platelet-vessel wall interaction in vivo. J Clin Invest. 1981; 68: 382–7.
11. Sinzinger H, Silberbauer K, Feigl W, Wagner O, Winter M, Auerswald W. Prostacyclin activity is diminished in different types of morphologically controlled human atherosclerotic lesions. Thromb Haemostas. 1979; 42: 803–4.
12. Dembinska-Kiec A, Gryglewska T, Zmuda A, Gryglewski RJ. The generation of prostacyclin by arteries and by the coronary vascular bed is reduced in experimental atherosclerosis in rabbits. Prostaglandins. 1977; 14: 1025–34.
13. Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980; 17: 317–27.
14. Levin RI, Jaffe EA, Weksler BB, Tack-Goldman K. Nitroglycerin stimulates synthesis of prostacyclin by cultured human endothelial cells. J Clin Invest. 1981; 67: 762–9.
15. Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet. 1979; 2: 1313–5.
16. Aspirin Myocardial Infarction Study Research Group. A randomized controlled trial of aspirin in persons recovered from myocardial infarction. JAMA. 1980; 243: 661–9.
17. Persantine-Aspirin Reinfarction Study Research Group. Persantine and aspirin in coronary heart disease. Circulation. 1980; 62: 449–61.
18. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982; 69: 1366–72.
19. Campbell WB, Johnson AR, Callahan KS, Graham RM. Anti-platelet activity of beta-adrenergic antagonists: inhibition of thromboxane synthesis and platelet aggregation in patients receiving long-term propranolol treatment. Lancet. 1981; 2: 1382–4.
20. Torosian M, Michelson EL, Morganroth J, MacVaugh H. Aspirin- and Coumadin-related bleeding after coronary-artery bypass graft surgery. Ann Intern Med. 1978; 89: 325–8.
21. Pantely GS, Goodnight SH Jr, Rahimtoola SH, et al. Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass: a controlled, randomized study. N Engl J Med. 1979; 301: 962–6.
22. McEnany MT, Salzman EW, Mundth ED, et al. The effect of antithrombotic therapy on patency rates of saphenous vein coronary artery bypass grafts. J Thorac Cardiovasc Surg. 1982; 83: 81–9.
23. Chesbro JH, Clements IP, Fuster V, et al. A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med. 1982; 307: 73–8.
24. Josa M, Lie JT, Bianco RL, Kaye MP. Reduction of thrombosis in canine coronary bypass vein grafts with dipyridamole and aspirin. Am J Cardiol. 1981; 47: 1248–54.
25. Rajah SM, Penny AF, Crow MJ, Pepper MD, Watson DA. The interaction of varying doses of dipyridamole and acetyl salicylic acid on the inhibition of platelet functions and their effect on bleeding time. Br J Clin Pharmacol. 1979; 8: 483–9.
26. Moneada S, Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet. 1978; 1: 1286–9.
27. Preston FE, Greaves M, Jackson CA. Cumulative inhibitory effect of daily 40 mg aspirin on prostacyclin synthesis. Lancet. 1981; 1: 1211–2.